Depression Research Studies
* Females with Depression needed for a clinical research study - Researchers at McLean Hospital are currently recruiting females diagnosed with clinical depression for a study on the effect of genetics on response to different antidepressant medications. Participants must: be female between the ages of 18 and 55; be currently depressed; not currently be taking any antidepressant medications; have no history of asthma; be willing to provide a blood sample. Participation in the study will entail taking one of two antidepressant medications for 10 weeks and having two MRI scans of your brain. You will be compensated up to $200 for your participation. All personal information will be kept strictly confidential. Please email Michelle at mbutman@mclean.harvard.edu if you are interested or would like more information.

* Planning to stop use of your antidepressant? If you are thinking about discontinuing use of your antidepressant in the near future, then you may be eligible for a clinical research study at McLean Hospital. We are looking for women who were depressed and have responded well to their antidepressant and wish to stop taking it for reasons not related to being in the study.

The aim of this study is to determine what changes occur in brain activity after people discontinue antidepressant medications. We will perform a total of three MRI scans to look for any changes. In addition, there will be periodic visits to meet with the study psychiatrist as well as periodic phone calls to monitor your progress over a period of up to 6 months. You may be compensated up to $575 for your participation in this study. Some of the requirements for eligibility include that you must: be a female between the ages of 18 and 45; be currently taking either fluoxetine (Prozac), citalopram (Celexa, Lexapro), paroxetine (Paxil), or sertraline (Zoloft) daily and wish to discontinue the drug; and have no history of asthma.

Depression is often a recurring illness and continuing on medication can reduce the number of recurrences. For this reason, if you meet study criteria you will be asked to have an additional evaluation by an independent psychiatrist to ensure that discontinuing your antidepressant is clinically reasonable for you. This evaluation is part of the study and will be provided at no cost to you.

If you would like more information, please contact Michelle at mbutman@mclean.harvard.edu and reference the “SSRI Discontinuation Study.”

* Seeking participants with depression for paid research at Stanford University - Researchers at Stanford University are conducting a research study on individuals with Major Depression. Study participants stay at Stanford Hospital 2 nights, have an MRI scan, diagnostic testing, blood drawn, and a test of adrenal functioning. Participation is confidential. All study-related costs are paid by Stanford University. Participants who complete the study will be paid $500. If you are experiencing symptoms of Major Depression, you may be eligible for screening at Stanford University. Call today to determine your eligibility (650) 723-1428 or psychresearch@stanford.edu. All calls are confidential.

* Research treatment for psychotic depression available at Stanford University - Treatment consists of 8 days of double-blind Mifepristone. Those who are still symptomatic, (if they received placebo) have the option of receiving active medication for an additional 8 days. Treatment is conducted as part of a research study on depression. As part of the study, patients undergo psychiatric testing, neurocognitive testing, 3 MRI scans and a total of 7 overnight blood draws to assess cortisol.

Patients must be between the ages of 18 to 85, have no unstable or untreated cardiovascular disease, endocrine or hormonal disorder, and no substance abuse or ECT in the past 6 months.

Patients can continue taking antidepressant and antipsychotic medication while in the study, and will receive $500 for completing the study. Please call today for more information or to refer a patient to the Stanford Department of Psychiatry at (650) 723-1428 or psychresearch@stanford.edu.

* Severe Depression Study - Feeling sad and depressed? Losing pleasure in engaging in daily activities? Difficulty concentrating or easily distracted? Suffering from low self-worth? If you or someone you know is experiencing any of these symptoms, you may be suffering from Severe Depression. Daniel D. Anderson, M.D., is conducting a research study for people with Severe Depression. If you qualify, you may be eligible to participate in a study testing the effectiveness of a research medication for the treatment of Severe Depression at no cost to you. If you would like additional information regarding this study and are between the ages of 18 and 75, please contact the office of Daniel D. Anderson, M.D., at (310) 891-0106.

* The Depression Research Clinic at Stanford University - The Stanford University Depression Research Clinic in the Department of Psychiatry and Behavioral Sciences is currently conducting several studies evaluating the effectiveness of new and investigational treatments for depression. If you are bothered by depression nearly every day, are 18 years or older, in good physical health, and are able to attend weekly appointments at Stanford between the hours of 8 a.m. and 5 p.m., Monday through Friday, you may be eligible. All of the studies involve an initial phone screen, during which time research staff will ask you questions to determine eligibility, explain the studies for which you may be eligible, and answer any questions that you may have. Participation is free and all calls are confidential. If you would like more information, please call the research study line at 650-723-8330.

* Transcranial Magnetic Stimulation (TMS) in the Treatment of Major Depression - A large, 16 center, randomized, placebo controlled trial to evaluate the safety and effectiveness of transcranial magnetic stimulation (TMS), a non-medication, non-invasive outpatient procedure, is currently underway. This trial will test a TMS device to evaluate its safety and ability to improve mood in patients with major depression. Information from this trial will be submitted to the US Food and Drug Administration (FDA) to support clearance which will allow physicians to prescribe TMS to treat patients with symptoms of depression. Inclusion Criteria: [list][*]Diagnosis of Major Depressive Disorder (MDD) [*]Age 18 – 70 years [*]Read and speak fluent English [*]Both males and females[/list:u] Exclusion Criteria: [list][*]Prior treatment with TMS [*]Metal objects in your head [*]Pregnancy or possible pregnancy [*]A diagnosis of psychosis, bipolar disorder, or OCD [*]Increased pressure in the brain for any reason [*]Intracardiac lines of any type [*]A diagnosis of a significant neurological disorder [*]A non-response to prior ECT[/list:u] Note: There are other less common factors which may prevent study enrollment. For information regarding TMS, trial specifics and locations, visit www.neuronetics.com. Individuals interested in participating in this trial, please call 1-800-345-8707.

*Families Affected by Depression: Washington University School of Medicine in St. Louis Missouri, is part of an international research project that is attempting to identify the genetic and environmental factors that may be responsible for Major Depressive Disorder. New information from the human genome project will be used to guide scientists to the genes that may determine which family members develop depression while others do not. Identification of these susceptibility genes will revolutionize our understanding of the disorder and will guide the design of new drugs to treat or even prevent this debilitating condition. Dr. Allen Roses, Worldwide Director of Genetics at GlaxoSmithKline, who are sponsors of the study, said: “There is strong evidence that points to a genetic predisposition to unipolar depression. The information available from the sequencing of the human genome together with the data we gather from this study will provide an unprecedented level of understanding which GlaxoSmithKline can feed into its research and development program to help speed up the discovery of new medicines.” A trained research assistant will ask each participant a series of confidential questions that address a broad range of life experiences that may or may not have occurred and that family members may or may not have experienced. Relatives who live too far away to visit the School of Medicine may be interviewed by telephone. Participants will also be asked to give a small blood sample for DNA studies. Blood samples may be drawn by local physicians and mailed back to our site if a personal visit from our staff is not possible.

Study criteria: We are looking for families where two or more full siblings (either brothers and/or sisters), sharing the same mother and father: [list][*]have experienced two or more episodes of depression – treatment is not provided by this study and IS NOT required for participation [*]are at least 18 years of age at the time of enrollment [*]have no history of Mania (either a mild or severe type)[/list:u] Additional family members may also participate and it is our hope that a significant proportion of families will be composed of these additional members (e.g, parents and "other" siblings). Participation will take approximately two to four hours to complete and monetary compensation for time and travel will be provided. For more information, please call or email Caroline Drain, M.H.S. at (314) 286-1345, rainc@msnotes.wustl.edu or call toll-free at 1-888-292-1210 or visit our web-site at www.zork.wustl.edu/depression